Knight Therapeutics (TSE:GUD) Sets New 1-Year High at $5.74

Knight Therapeutics Inc. (TSE:GUDGet Rating) hit a new 52-week high on Thursday . The stock traded as high as C$5.74 and last traded at C$5.74, with a volume of 39700 shares changing hands. The stock had previously closed at C$5.70.

Wall Street Analysts Forecast Growth

Separately, Raymond James set a C$7.50 price objective on shares of Knight Therapeutics and gave the company an “outperform” rating in a report on Friday, April 1st. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of C$6.92.

Knight Therapeutics Trading Up 1.4 %

The company’s fifty day simple moving average is C$5.37 and its two-hundred day simple moving average is C$5.38. The company has a quick ratio of 2.05, a current ratio of 2.73 and a debt-to-equity ratio of 5.64. The company has a market capitalization of C$663.67 million and a price-to-earnings ratio of -105.27.

Knight Therapeutics (TSE:GUDGet Rating) last posted its earnings results on Thursday, May 12th. The company reported C($0.02) earnings per share for the quarter, topping the consensus estimate of C($0.04) by C$0.02. The firm had revenue of C$63.81 million during the quarter, compared to analyst estimates of C$52.80 million. Research analysts forecast that Knight Therapeutics Inc. will post -0.02 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Long Zone Holdings Inc. acquired 18,000 shares of the company’s stock in a transaction that occurred on Thursday, June 16th. The shares were acquired at an average cost of C$5.18 per share, for a total transaction of C$93,240.00. Following the completion of the acquisition, the insider now directly owns 21,723,933 shares in the company, valued at approximately C$112,529,972.94. In related news, insider Long Zone Holdings Inc. acquired 18,000 shares of the company’s stock in a transaction that occurred on Thursday, June 16th. The shares were acquired at an average cost of C$5.18 per share, for a total transaction of C$93,240.00. Following the completion of the acquisition, the insider now directly owns 21,723,933 shares in the company, valued at approximately C$112,529,972.94. Also, Director Samira Sakhia bought 19,455 shares of the firm’s stock in a transaction that occurred on Monday, June 20th. The stock was acquired at an average cost of C$5.14 per share, with a total value of C$99,998.70. Following the transaction, the director now owns 158,954 shares of the company’s stock, valued at approximately C$817,023.56. Insiders have purchased a total of 76,760 shares of company stock worth $396,639 over the last ninety days.

About Knight Therapeutics

(Get Rating)

Knight Therapeutics Inc, a specialty pharmaceutical company, develops, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices in Canada, Latin America, and internationally. It offers Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib to treat metastatic cholangiocarcinoma; Trelstar for advanced prostate cancer and for pain associated with endometriosis; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic adenocarcinoma; Halaven for metastatic breast cancer and doft tissue sarcoma; and Lenvima for differentiated thyroid cancer, advanced renal cell cancer, and unresectable hepatocellular carcinoma.

See Also

Receive News & Ratings for Knight Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Knight Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.